What is PCOS?
Polycystic ovarian syndrome (PCOS) is a common hormonal disorder that affects around 10–15% of women of reproductive age worldwide. Irregular menstrual cycles, signs of excess androgen hormones, including acne and hirsutism, insulin resistance, obesity, and infertility, frequently occur as a result of this condition. It has become more common for women to turn to Tirzepatide for PCOS.
Weight Loss is the Primary Management Goal in PCOS
The primary intervention is weight loss for most patients with PCOS, as weight loss can restore ovulatory cycles and improve metabolic abnormalities that pose health risks to women with PCOS.
Although weight loss in patients who maintain long-term lifestyle changes, such as caloric restriction and exercise, can resolve ovulatory cycles and correct metabolic imbalances, it is difficult for many women to sustain long-term change through lifestyle modification alone, and the weight loss tends to return after a year or less.
Other treatments currently used to manage PCOS aim to correct specific abnormalities. Goals of management include:
- Correction of metabolic abnormalities, which increase the risk of type 2 diabetes and cardiovascular disease.
- Management of symptoms of excess androgens: acne, excess hair growth, loss of scalp hair
- Preventing hyperplasia of the uterine lining, which can lead to uterine cancer
- Contraception for women who do not wish to become pregnant, as irregular cycles can result in unintended pregnancy.
- Ovulation induction for women who desire pregnancy.
Current Treatments for PCOS
- Combined oral contraceptives are the current mainstay of treatment.
- Although these medications carry an increased risk of venous thromboembolic disease (pulmonary emboli, deep vein thrombosis) in women who have PCOS, it is similar to the risk in women without PCOS.
- Alternative options such as progestin-only mini-pills or progestin-releasing IUDs reduce the risk of hyperplasia of the uterine lining, a risk factor for endometrial cancer, and provide a contraceptive alternative.
- Cosmetic treatments or direct hair removal are usually recommended initially for women with hirsutism caused by excess androgen hormones.
- Antiandrogenic medications may be prescribed after 6 months of combined oral contraceptive therapy fails to achieve an adequate response to androgenic features.
- Metformin or other antidiabetic medications are prescribed for insulin resistance
or type 2 diabetes.
- Metformin was once believed to improve hirsuitism in PCOS, but is less effective than treatment with combined oral contraceptives or anti-androgens.
- Statin medications are prescribed for related lipid disorders, in addition to the usual lifestyle and dietary changes.
Weight Loss is a Key Component of the Treatment of PCOS
Most experts suggest that weight loss through lifestyle changes like diet and exercise should begin before women with PCOS start treatment to induce regular ovulation with combined oral contraceptives and antiandrogenic therapies.
Women with PCOS, like women without PCOS, have been found to have variable responses to lifestyle changes like diet and exercise. More than a third of women with PCOS in a small long-term study had a complete response after approximately 20 months of following a 1200-1400 kcal/day diet for 6 months, followed by mild caloric restriction and increased physical activity. However, many studies have found that maintaining lifestyle changes and sustained weight loss is inconsistent, with most weight regained within a year.
Tirzepatide’s Potential Benefits for the Treatment of PCOS
PCOS is closely linked to insulin resistance, even in women who are at a healthy weight. When insulin levels are excessively high, the ovaries create too much androgen. This can make ovulation erratic and cause unwanted symptoms like infertility, androgenic symptoms like acne, and excessive abnormal hair growth.
In the SURMOUNT-1 study, patients without diabetes lost 15% to 21% of their initial body weight, depending on the dose. These results are highly important because decreasing weight can usually help with ovulation and androgen symptoms in women with PCOS.
Prior studies utilizing GLP-1 receptor agonists (e.g., liraglutide and semaglutide) in women with PCOS have demonstrated benefits in weight control, insulin resistance, and waist circumference, as well as signs of improved ovulatory regularity. Tirzepatide may be significantly more effective due to its novel dual receptor mechanism of action.
Tirzepatide and PCOS: What Lies Ahead
Tirzepatide may help women with PCOS by:
- Increasing insulin sensitivity and reducing insulin resistance are primary features of PCOS.
- Improving ovulatory regulation and fertility
- Weight is the most important element affecting ovulatory cycles and fertility.
- Increasing and sustaining weight loss.
- The SURMOUNT-4 study, a randomized clinical trial of continued maintenance of weight reduction in adults with obesity, treated participants with weekly doses of tirzepatide for 36 weeks. The mean weight reduction at 36 weeks was 20.9%, and participants were randomized to receive either a placebo or continued tirzepitide.
- Participants who were randomized to tirzepatide instead of placebo from week 36 for a further 52 weeks were found to maintain at least 80% of their weight loss, compared to 16.6% of those who were randomized to the placebo.
- Hirsuitism and hyperandrogenism.
- Lowering insulin levels may limit the production of ovarian androgens, which could make cycles more regular and possibly boost conception.
- Reducing metabolic and cardiovascular risk
- Women with PCOS are more prone to developing type 2 diabetes and heart disease. Tirzepatide’s effects may lessen these risks over time.
Additional research will answer these questions, as there is a good deal of interest in the potential of tirzepatide for the management of PCOS
References
Anala AD, Saifudeen ISH, Ibrahim M, Nanda M, Naaz N, Atkin SL. The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. J Clin Med. 2023;12(14):4575. Published 2023 Jul 10. doi:10.3390/jcm1214457 Link: https://pubmed.ncbi.nlm.nih.gov/37510690/
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 Link: https://jamanetwork.com/journals/jama/fullarticle/2812936
Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4646-4654. doi:10.1210/jc.2013-2374 Link: https://pubmed.ncbi.nlm.nih.gov/24092830/
Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5 Link: https://pubmed.ncbi.nlm.nih.gov/34819089/
Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008;9(10):987-992. doi:10.2459/JCM.0b013e32830b58d4 Link: https://pubmed.ncbi.nlm.nih.gov/18799960/
Hoeger KM. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50(1):277-294. doi:10.1097/GRF.0b013e31802f54c8 Link: https://pubmed.ncbi.nlm.nih.gov/17304042/
Moreira RO, Valerio CM, Hohl A, et al. Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68:e240422. Published 2024 Nov 25. doi:10.20945/2359-4292-2024-0422 Link: https://pubmed.ncbi.nlm.nih.gov/39664998/
Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update. 2004;10(3):267-280. doi:10.1093/humupd/dmh018 Link: https://pubmed.ncbi.nlm.nih.gov/15140873/
Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164(1):53-60. doi:10.1530/EJE-10-0692 Link: https://pubmed.ncbi.nlm.nih.gov/20956435/
Sassin MD, A. M., SangiHaghpeykar MD, PhD, H., Kjersti, S., Aagaard, PhD, M., & Detti MD, L. (2023, October). Effects of metformin alone versus metformin and tirzepatide on weight loss in patients with polycystic ovarian syndrome (PCOS) [Poster session]. POSTER ABSTRACT SESSION: REPRODUCTIVE MEDICINE- NON-INFERTILITY . Link: https://www.fertstert.org/article/S0015-0282(23)01397-3/fulltext
Skow MA, Bergmann NC, Knop FK. Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes Obes Metab. 2016;18(9):847-854. doi:10.1111/dom.12685 Link: https://pubmed.ncbi.nlm.nih.gov/27160961/
van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;20
15(4):CD010334. Published 2015 Apr 28. doi:10.1002/14651858.CD010334.pub2 Link: https://pubmed.ncbi.nlm.nih.gov/25918921/
Precision Telemed Clickable Links
Compounded Tirzepatide
Compounded Semaglutide
Sermorelin Peptide
NAD+ Injections
Testosterone Replacement Therapy
Hair Loss
Erectile Dysfunction